ESOC 2026

Lys Therapeutics is pleased to participate in #ESOC 2026, the 12th European Stroke Organisation Conference, taking place this week in #Maastricht, the Netherlands.

Dr. Manuel Blanc, Co-founder & CEO, and Dr. Jean-Baptiste BERTRAND, Head of Clinical Operations, look forward to connecting with the European and international stroke community to discuss the latest advances in #cerebrovascular research, #neuroinflammation, and #clinical translation.

At Lys Therapeutics, we are advancing #LYS241, our first-in-class monoclonal antibody designed to selectively block the #pathological tPA-NMDAr interaction, with the ambition to protect the neurovascular unit and address key mechanisms driving ischemic stroke progression, including blood-brain barrier dysfunction, neuroinflammation, and excitotoxicity.

We look forward to insightful scientific and strategic discussions at ESOC 2026.

#ESOC2026 #Stroke #StrokeResearch #Neuroinflammation #BloodBrainBarrier #NeurovascularUnit #Biotech #LYS241 #LysTherapeutics